We have written earlier that Edtech and Martech player CL Educate is a stock in a positive upcycle. FY22 has already seen a chain of positive developments. CL’s newsletter for its Test Prep business for Nov’21 shows the rapid pace of developments at the company. Some key snippets: CL is…
Read More
After the FY21 year-end result of CL Educate, we wrote in June’21: In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. Then after Q1 FY22 results, we wrote in Aug’21: After 2 years –…
Read More
We recorded 79 VC/PE transactions pertaining to the global life sciences sector for September 2021, aggregating to a sum of USD 3.3B, as against 96 transactions and USD5.6B in Sep’20. The USA recorded 49 transactions aggregating to a total investment of USD 2.2B. China reported a totally out of character…
Read More
The other day I was talking to a person who is an early-stage investor. He was looking to invest in a food business. He explained to me his criterion: he said his fund wanted to invest in a sales-multiple food business. This foxed me. I have heard of packaged food…
Read More After 2 years – FY20 and FY21 – of hanging tough, CL Educate appears to have entered a cycle of positive developments from FY22. Q1 FY22 results showed early indications of this. Firstly, there are signs of return to growth, despite Covid-2 wave still going strong in Q1 FY22. Stand…
Read More We recorded 114 VC/PE transactions pertaining to the global life sciences sector for June 2021, aggregating to a sum of USD 6.47B. The USA recorded 69 transactions aggregating to a total investment of USD 3.26B. China reported investment of USD 886m from 11 VC/PE transactions. Rest of the world accounted…
Read More FY21 didn’t turn out too bad for CL Educate. In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. That is not to say it was a rosy FY21 for CL. The global scourge Covid…
Read More
Chemcrux Enterprises suffered only a 7% revenue drop and 17% EBITDA drop in FY21, despite losing over 23% of productive days due to plant closure, and Covid related production constraints in FY21. Highlights of the FY21 results: FY21 full year sales came in at Rs 533m, 7% drop over sales…
Read More We recorded 94 VC/PE transactions pertaining to the global life sciences sector for May 2021, aggregating to a sum of USD 6.56B. The USA recorded 60 transactions aggregating to a total investment of USD 3.3B. China reported investment of USD 1.8B from 12 VC/PE transactions. Rest of the world accounted…
Read More We recorded 131 VC/PE transactions pertaining to the global life sciences sector for April 2021, aggregating to a sum of USD 6.5B. The USA recorded 88 transactions with total investment of USD 3.8B. China reported investment of USD 585m from 12 VC/PE transactions. Rest of world accounted for 31 transactions…
Read More